Better Health for All

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company entirely focused on developing novel therapies for significant unmet medical needs, with 100% of its R&D and capital allocation dedicated to improving health outcomes. Its lead product candidate, EP-104GI for Eosinophilic Esophagitis (EoE), has shown near complete improvement in tissue health (94-97% improvement in Cohort 9 at week 12)

and high clinical remission rates (58% at 12 weeks, 79% at 24 weeks, 67% at 52 weeks). The company believes EP-104GI has the potential to significantly improve upon the current standard of care, with efficacy outcomes well beyond published results for leading approved therapies. Another candidate, EP-104IAR for knee osteoarthritis, demonstrated a statistically significant reduction in WOMAC pain score. The company has reported an excellent safety record for EP-104GI, with no serious adverse events across multiple cohorts and over 200 patient-months of follow-up, and no cases of oral or gastrointestinal candidiasis. EP-104IAR was also generally well-tolerated with no treatment-related deaths or serious adverse events. Clinical trials are conducted according to ethical guidelines, registered with ClinicalTrials.gov and the EU Clinical Trials Register, and include ethical approval, informed consent, a Safety Committee, and a Clinical Advisory Board. However, one trial noted limited ethnic diversity in the study population. The company acknowledges that EoE can lead to mental health issues and is considering indications for prevention of strictures in Barrett's esophagus, and intends to include adolescent patients in future Phase 3 programs for EP-104GI.

Fair Money & Economic Opportunity

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the research and development of novel therapies. The company does not offer lending, deposit, or other financial services to consumers.

Therefore, all KPIs related to financial services, such as customer segments, pricing, fees, loan books, customer financial data, lending compliance, wealth building outcomes, community finance reinvestment, financial literacy programs, debt products, geographic access points for financial services, and financial product simplicity, are not applicable to its core business model.

Fair Pay & Worker Respect

The company has an employee count of 33.

No regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles. There is no specific data available for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, or health insurance coverage.

Honest & Fair Business

Eupraxia Pharmaceuticals Inc. has a formal Whistleblower Policy, which includes a hotline for anonymous reporting of accounting or auditing concerns and explicitly prohibits retaliation.

However, there is no evidence regarding independent investigation processes or resolution times for these reports. The company restated its financial statements for 2022 and 2021 due to accounting adjustments, which averages to 0.4 restatements per year over the past five years. The Nominating and Corporate Governance Committee Charter states that all three or more committee members must be independent, and the committee periodically assesses the independence of the full board. The company's Code of Business Conduct and Ethics includes an anti-corruption policy that prohibits bribery and other unethical practices, but there is no information on the frequency or effectiveness of training for this policy.

Kind to Animals

The provided articles offer no specific, concrete data points regarding Eupraxia Pharmaceuticals Inc.'s animal welfare practices. While one article mentions that the company's research and development activities could be affected or delayed as a result of possible restrictions on animal testing,

this statement is a risk disclosure and does not provide details on the company's animal testing policy, the volume of animals used, or any alternative methods employed. Consequently, there is insufficient evidence to score any of the 'Kind to Animals' KPIs according to the rubric's quantitative thresholds.

Planet-Friendly Business

The provided articles do not contain any specific, concrete data points or facts related to Eupraxia Pharmaceuticals Inc.'s environmental performance, sustainability initiatives, or climate-related disclosures.

Therefore, no KPIs under the 'Planet-Friendly Business' value can be scored based on the evidence provided.

Respect for Cultures & Communities

Eupraxia Pharmaceuticals, a clinical-stage biotechnology company, has no formal partnerships with indigenous or local community groups mentioned in the provided articles, which aligns with a business model where such partnerships may not be applicable.

No cultural appropriation incidents have been reported, and the company's operations, focused on research and clinical trials, suggest limited direct interaction with cultural heritage. Similarly, there is no specific cultural impact assessment protocol, which is consistent with its business model. The company's Code of Business Conduct and Ethics, amended August 18, 2025, outlines standard internal grievance mechanisms for company personnel, including a Whistleblower Hotline, and prohibits retaliation; however, these are not explicitly community-specific.